Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea
· Delayed Price · Currency is KRW 3,875.00
+55.00 (1.44%)
At close: Apr 17, 2025, 3:30 PM KST
Bukwang Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 160,087 | 125,928 | 190,909 | 182,491 | 169,660 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | -0 | Upgrade
|
| Revenue | 160,087 | 125,928 | 190,909 | 182,491 | 169,660 | Upgrade
|
| Revenue Growth (YoY) | 27.13% | -34.04% | 4.61% | 7.56% | 0.87% | Upgrade
|
| Cost of Revenue | 86,023 | 79,012 | 111,763 | 106,942 | 98,319 | Upgrade
|
| Gross Profit | 74,064 | 46,916 | 79,147 | 75,550 | 71,341 | Upgrade
|
| Selling, General & Admin | 45,966 | 51,274 | 49,797 | 43,477 | 45,373 | Upgrade
|
| Research & Development | 23,431 | 34,551 | 24,274 | 22,465 | 18,032 | Upgrade
|
| Other Operating Expenses | 2,225 | 2,078 | 1,345 | 1,317 | 1,563 | Upgrade
|
| Operating Expenses | 72,447 | 84,413 | 79,377 | 69,928 | 67,313 | Upgrade
|
| Operating Income | 1,618 | -37,497 | -230.64 | 5,622 | 4,028 | Upgrade
|
| Interest Expense | -6,490 | -3,808 | -1,760 | -1,408 | -1,515 | Upgrade
|
| Interest & Investment Income | 4,419 | 3,080 | 1,440 | 268.16 | 1,313 | Upgrade
|
| Earnings From Equity Investments | 343.13 | -1,501 | 58.57 | -1,361 | -2,838 | Upgrade
|
| Currency Exchange Gain (Loss) | -64.59 | -177.44 | 88.47 | 322.31 | -2,105 | Upgrade
|
| Other Non Operating Income (Expenses) | -1,755 | 867.73 | -113.73 | 33.63 | -401.19 | Upgrade
|
| EBT Excluding Unusual Items | -1,930 | -39,036 | -517.65 | 3,477 | -1,518 | Upgrade
|
| Impairment of Goodwill | -915.64 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 738.9 | -564.4 | -567.47 | 90.53 | -3,297 | Upgrade
|
| Gain (Loss) on Sale of Assets | 53.75 | 30.64 | 52.25 | 220.05 | 54.25 | Upgrade
|
| Asset Writedown | -8,670 | - | - | - | -3,539 | Upgrade
|
| Other Unusual Items | 7,753 | - | - | - | - | Upgrade
|
| Pretax Income | -2,970 | -39,569 | -1,033 | 3,787 | -8,300 | Upgrade
|
| Income Tax Expense | 489.25 | -5,163 | 3,216 | 6,584 | 1,805 | Upgrade
|
| Earnings From Continuing Operations | -3,459 | -34,407 | -4,249 | -2,797 | -10,105 | Upgrade
|
| Minority Interest in Earnings | 817.44 | 3,077 | 1,774 | 1,880 | 2,902 | Upgrade
|
| Net Income | -2,641 | -31,330 | -2,475 | -916.62 | -7,203 | Upgrade
|
| Net Income to Common | -2,641 | -31,330 | -2,475 | -916.62 | -7,203 | Upgrade
|
| Shares Outstanding (Basic) | 68 | 68 | 68 | 68 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 68 | 68 | 68 | 68 | 69 | Upgrade
|
| Shares Change (YoY) | - | - | -0.01% | -0.25% | -4.24% | Upgrade
|
| EPS (Basic) | -38.59 | -457.67 | -36.15 | -13.39 | -104.95 | Upgrade
|
| EPS (Diluted) | -39.00 | -458.00 | -36.15 | -13.39 | -105.00 | Upgrade
|
| Free Cash Flow | 32,424 | -12,196 | 12,163 | 25,740 | -1,194 | Upgrade
|
| Free Cash Flow Per Share | 473.65 | -178.17 | 177.69 | 375.98 | -17.40 | Upgrade
|
| Gross Margin | 46.27% | 37.26% | 41.46% | 41.40% | 42.05% | Upgrade
|
| Operating Margin | 1.01% | -29.78% | -0.12% | 3.08% | 2.37% | Upgrade
|
| Profit Margin | -1.65% | -24.88% | -1.30% | -0.50% | -4.25% | Upgrade
|
| Free Cash Flow Margin | 20.25% | -9.69% | 6.37% | 14.11% | -0.70% | Upgrade
|
| EBITDA | 5,724 | -33,204 | 4,886 | 10,465 | 10,186 | Upgrade
|
| EBITDA Margin | 3.57% | -26.37% | 2.56% | 5.73% | 6.00% | Upgrade
|
| D&A For EBITDA | 4,106 | 4,292 | 5,117 | 4,843 | 6,158 | Upgrade
|
| EBIT | 1,618 | -37,497 | -230.64 | 5,622 | 4,028 | Upgrade
|
| EBIT Margin | 1.01% | -29.78% | -0.12% | 3.08% | 2.37% | Upgrade
|
| Effective Tax Rate | - | - | - | 173.85% | - | Upgrade
|
| Advertising Expenses | 6,307 | 12,764 | 12,181 | 6,622 | 8,784 | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.